Combined Immunotherapy and Targeted Therapies for Cancer Treatment : Recent Advances and Future Perspectives
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
The previous year's worldview for cancer treatment has advanced from general to more precise therapeutic approaches. Chemotherapies were first distinguished as the most reliable and brief therapy with promising outcomes in cancer patients. However, patients could also suffer from severe toxicities resulting from chemotherapeutic drug usage. An improved comprehension of cancer pathogenesis has led to new treatment choices, including tumor-targeted therapy and immunotherapy. Subsequently, cancer immunotherapy and targeted therapy give more hope to patients since their combination has tremendous therapeutic efficacy. The immune system responses are also initiated and modulated by targeted therapies and cytotoxic agents, which create the principal basis that when targeted therapies are combined with immunotherapy, the clinical outcomes are of excellent efficacy, as presented in this review. This review focuses on how immunotherapy and targeted therapy are applicable in cancer management and treatment. Also, it depicts promising therapeutic results with more extensive immunotherapy applications with targeted therapy. Further elaborate that immune system responses are also initiated and modulated by targeted therapies and cytotoxic agents, which create the principal basis that this combination therapy with immunotherapy can be of great outcome clinically.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 23(2023), 4 vom: 20., Seite 251-264 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 09.03.2023 Date Revised 15.04.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1568009623666221020104603 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347930573 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347930573 | ||
| 003 | DE-627 | ||
| 005 | 20231226035009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1568009623666221020104603 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347930573 | ||
| 035 | |a (NLM)36278447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined Immunotherapy and Targeted Therapies for Cancer Treatment |b Recent Advances and Future Perspectives |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2023 | ||
| 500 | |a Date Revised 15.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a The previous year's worldview for cancer treatment has advanced from general to more precise therapeutic approaches. Chemotherapies were first distinguished as the most reliable and brief therapy with promising outcomes in cancer patients. However, patients could also suffer from severe toxicities resulting from chemotherapeutic drug usage. An improved comprehension of cancer pathogenesis has led to new treatment choices, including tumor-targeted therapy and immunotherapy. Subsequently, cancer immunotherapy and targeted therapy give more hope to patients since their combination has tremendous therapeutic efficacy. The immune system responses are also initiated and modulated by targeted therapies and cytotoxic agents, which create the principal basis that when targeted therapies are combined with immunotherapy, the clinical outcomes are of excellent efficacy, as presented in this review. This review focuses on how immunotherapy and targeted therapy are applicable in cancer management and treatment. Also, it depicts promising therapeutic results with more extensive immunotherapy applications with targeted therapy. Further elaborate that immune system responses are also initiated and modulated by targeted therapies and cytotoxic agents, which create the principal basis that this combination therapy with immunotherapy can be of great outcome clinically | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a T-cell | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a dendritic-cell | |
| 650 | 4 | |a immunity | |
| 650 | 4 | |a targeted-therapies | |
| 650 | 7 | |a Cytotoxins |2 NLM | |
| 700 | 1 | |a Li, Yafei |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Qiuxia |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Zhiqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Daijie |e verfasserin |4 aut | |
| 700 | 1 | |a Umar Shinge, Shafiu A |e verfasserin |4 aut | |
| 700 | 1 | |a Muluh, Tobias Achu |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Xiaohong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g 23(2023), 4 vom: 20., Seite 251-264 |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:4 |g day:20 |g pages:251-264 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568009623666221020104603 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 4 |b 20 |h 251-264 | ||